Effect of new legislation in Germany on prevalence and harm of synthetic cannabinoids

References

• European Monitoring Centre for Drugs and Drug Addiction. European drug report 2020: Trends and development. Luxembourg: Publications Office of the European Union; 2021.
   Google Scholar
• Miliano C, Serpelloni G, Rimondo C, et al. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci. 2016;10:153.
   PubMed Web of Science ®Google Scholar
• Evans-Brown M, Sedefov R. Responding to new psychoactive substances in the European union: early warning, risk assessment, and control measures. Handb Exp Pharmacol. 2018;252:3–49.
   PubMedGoogle Scholar
• Giorgetti A, Pascali JP, Fais P, et al. Molecular mechanisms of action of novel psychoactive substances (NPS). A new threat for young drug users with forensic-toxicological implications. Life (Basel). 2021;11(5):440.
   PubMed Web of Science ®Google Scholar
• Hurd YL, Manzoni OJ, Pletnikov MV, et al. Cannabis and the developing brain: insights into its long-lasting effects. J Neurosci. 2019;39(42):8250–8258.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Carmo H, Carvalho F, et al. Synthetic cannabinoids and their impact on neurodevelopmental processes. Addict Biol. 2020;25(2):e12824.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in Europe: Legislation and prosecution - current challenges and solutions. Luxembourg: Publications Office of the European Union; 2016.
   Google Scholar
• Yoganathan P, Claridge H, Chester L, et al. Synthetic cannabinoid-related deaths in England, 2012–2019. Cannabis Cannabinoid Res. 2022;7(4):516–525.
   PubMedGoogle Scholar
• Al-Banaa I, Hawkins L, Hill SL, et al. Effect of the UK psychoactive substances act 2016 on episodes of toxicity related to new psychoactive substances as reported to the national poisons information service. A time series analysis. International Journal of Drug Policy. 2020;77:102672.
   PubMed Web of Science ®Google Scholar
• UNODC. Early warning on new psychoactoive subdstances [Internet] [cited 2022. Jan 10]. Available from: https://www.unodc.org/LSS/Page/NPS/LegalResponses.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids in Europe - a review. Luxembourg: Publications Office of the European Union; 2021.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs: Synthetic cannabinoids in Europe. Luxembourg: Publications Office of the European Union; 2017.
   Google Scholar
• Gomes de Matos E, Hannemann T-V, Atzendorf J, et al. The consumption of new psychoactive substances and methamphetamine. Deutsches Aerzteblatt Online. 2018;115(4):49–55.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Müller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol (Phila). 2018;56(6):404–411.
   PubMed Web of Science ®Google Scholar
• Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–213.
   PubMed Web of Science ®Google Scholar
• Angerer V, Süβenbach F, Hirschinger N, et al. Validated LC–MS/MS method for qualitative and quantitative analysis of 75 synthetic cannabinoids in serum 53rd Annual Meeting of International Association of Forensic Toxicology, TIAFT 2015. p p. 126.
   Google Scholar
• Franz F, Angerer V, Jechle H, et al. Immunoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency. Clin Chem Lab Med. 2017;55(9):1375–1384.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Kneisel S, Girreser U, et al. Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-(5-fluoropentyl)-1H-indol-3yl-(4-methylnaphthalen-1-yl)methanone using GC-MS, NMR analysis and a flash chromatography system. Forensic Sci Int. 2012;220(1-3):e17-22–e22.
   PubMed Web of Science ®Google Scholar
• Grigg J, Killian JJ, Matthews S, et al. The impact of legislation on acute synthetic cannabinoid harms resulting in ambulance attendance. Int J Drug Policy. 2020;79:102720.
   PubMed Web of Science ®Google Scholar
• Glue P, Courts J, Gray A, et al. Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. N Z Med J. 2016;129(1433):37–40.
   PubMedGoogle Scholar
• Webb NE, Wood DM, Greene SL, et al. Change in the new psychoactive substances associated with emergency department acute toxicity presentations associated with the introduction of the UK 2016 psychoactive substances act. Clin Toxicol (Phila). 2019;57(1):36–41.
   PubMed Web of Science ®Google Scholar
• Gilley M, Brent J, Calello DP, et al. Synthetic cannabinoid exposure in adolescents presenting for emergency care. Pediatr Emerg Care. 2021;37(1):e13–e16.
   PubMed Web of Science ®Google Scholar
• Anderson SAR, Oprescu AM, Calello D, et al. Neuropsychiatric sequelae in adolescents with acute synthetic cannabinoid toxicity. Pediatrics. 2019;144(2):e20182690.
   PubMed Web of Science ®Google Scholar
• Kraus L, Schiemann A, Verthein U, et al. Evaluation der Auswirkungen des Neue-psychoaktive-Stoffe-Gesetzes (NpSG) [Internet] [cited 10.01.22]. Available from: https://www.ift.de/fileadmin/user_upload/Literatur/Berichte/Kraus_et_al_2020_NpSG-Abschlussbericht.pdf.
   Google Scholar
• Werse B, Kamphausen G, Martens J. Monitoring-Systems Drogentrends (MoSyD): Annual report 2018. [Internet] [cited 2022 Jan 10]. Available from: https://www.uni-frankfurt.de/83212689/MoSyD_Jahresbericht_2018_final.pdf.
   Google Scholar
• Ralphs R, Gray P, Sutcliffe OB. The impact of the 2016 psychoactive substances act on synthetic cannabinoid use within the homeless population: markets, content and user harms. Int J Drug Policy. 2021;97:103305.
   PubMed Web of Science ®Google Scholar
• Halter S, Haschimi B, Mogler L, et al. Impact of legislation on NPS markets in Germany - the rise and fall of 5F-ADB. Drug Test Anal. 2020;12(6):853–856.
   PubMed Web of Science ®Google Scholar
• Wolfe CE, Wood DM, Dines A, et al. Seizures as a complication of recreational drug use: analysis of the Euro-DEN plus data-set. Neurotoxicology. 2019;73:183–187.
   PubMed Web of Science ®Google Scholar
• Thomas SHL, Vidlera D, Officer J. Changing patterns of synthetic cannabinoid receptor agonists encountered in UK emergency departments. Clinical Toxicology. 2021;59(6):538–538.
   Web of Science ®Google Scholar
• Halter S, Angerer V, Röhrich J, et al. Cumyl-PEGACLONE: a comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Drug Test Anal. 2019;11(2):347–349.
   PubMed Web of Science ®Google Scholar
• Giorgetti A, Mogler L, Halter S, et al. Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. Forensic Toxicol. 2020;38(2):314–326.
   Web of Science ®Google Scholar